RXi Technology Shows Potential as miRNA Mimic In Vitro | GenomeWeb

RXi Pharmaceuticals said this week that, in collaboration with Miragen Therapeutics, it has generated positive in vitro data demonstrating the use of its self-delivering RNAi agents to enhance the activity of a particular microRNA.

Specifically, the companies used the self-delivering molecules to create an miRNA mimic capable of down-regulating a reporter gene whose expression is controlled by the microRNA in cell culture model systems developed by Miragen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.